164 related articles for article (PubMed ID: 28301507)
1. TP53 alterations in primary and secondary Sézary syndrome: A diagnostic tool for the assessment of malignancy in patients with erythroderma.
Gros A; Laharanne E; Vergier M; Prochazkova-Carlotti M; Pham-Ledard A; Bandres T; Poglio S; Berhouet S; Vergier B; Vial JP; Chevret E; Beylot-Barry M; Merlio JP
PLoS One; 2017; 12(3):e0173171. PubMed ID: 28301507
[TBL] [Abstract][Full Text] [Related]
2. Early clinical manifestations of Sézary syndrome: A multicenter retrospective cohort study.
Mangold AR; Thompson AK; Davis MD; Saulite I; Cozzio A; Guenova E; Hodak E; Amitay-Laish I; Pujol RM; Pittelkow MR; Gniadecki R
J Am Acad Dermatol; 2017 Oct; 77(4):719-727. PubMed ID: 28709694
[TBL] [Abstract][Full Text] [Related]
3. Loss of the candidate tumor suppressor ZEB1 (TCF8, ZFHX1A) in Sézary syndrome.
Caprini E; Bresin A; Cristofoletti C; Helmer Citterich M; Tocco V; Scala E; Monopoli A; Benucci R; Narducci MG; Russo G
Cell Death Dis; 2018 Dec; 9(12):1178. PubMed ID: 30518749
[TBL] [Abstract][Full Text] [Related]
4. Sézary Syndrome: Translating Genetic Diversity into Personalized Medicine.
Chevret E; Merlio JP
J Invest Dermatol; 2016 Jul; 136(7):1319-1324. PubMed ID: 27342034
[TBL] [Abstract][Full Text] [Related]
5. Molecular staging of lymph nodes from 60 patients with mycosis fungoides and Sézary syndrome: correlation with histopathology and outcome suggests prognostic relevance in mycosis fungoides.
Fraser-Andrews EA; Mitchell T; Ferreira S; Seed PT; Russell-Jones R; Calonje E; Whittaker SJ
Br J Dermatol; 2006 Oct; 155(4):756-62. PubMed ID: 16965425
[TBL] [Abstract][Full Text] [Related]
6. The tumour suppressor p53 is frequently nonfunctional in Sézary syndrome.
Lamprecht B; Kreher S; Möbs M; Sterry W; Dörken B; Janz M; Assaf C; Mathas S
Br J Dermatol; 2012 Aug; 167(2):240-6. PubMed ID: 22384858
[TBL] [Abstract][Full Text] [Related]
7. Genetic rearrangements result in altered gene expression and novel fusion transcripts in Sézary syndrome.
Iżykowska K; Przybylski GK; Gand C; Braun FC; Grabarczyk P; Kuss AW; Olek-Hrab K; Bastidas Torres AN; Vermeer MH; Zoutman WH; Tensen CP; Schmidt CA
Oncotarget; 2017 Jun; 8(24):39627-39639. PubMed ID: 28489605
[TBL] [Abstract][Full Text] [Related]
8. A new molecular paradigm in mycosis fungoides and Sézary syndrome.
Elenitoba-Johnson KS; Wilcox R
Semin Diagn Pathol; 2017 Jan; 34(1):15-21. PubMed ID: 28024703
[TBL] [Abstract][Full Text] [Related]
9. Overexpression of c-myb in leukaemic and non-leukaemic variants of cutaneous T-cell lymphoma.
Poenitz N; Simon-Ackermann J; Gratchev A; Qadoumi M; Klemke CD; Stadler R; Kremer A; Radenhausen M; Henke U; Assaf C; Utikal J; Goerdt S; Dippel E
Dermatology; 2005; 211(2):84-92. PubMed ID: 16088151
[TBL] [Abstract][Full Text] [Related]
10. Cytologic evaluation of lymphadenopathy associated with mycosis fungoides and Sezary syndrome: role of immunophenotypic and molecular ancillary studies.
Pai RK; Mullins FM; Kim YH; Kong CS
Cancer; 2008 Oct; 114(5):323-32. PubMed ID: 18798522
[TBL] [Abstract][Full Text] [Related]
11. Erythrodermic mycosis fungoides and Sézary syndrome treated with extracorporeal photopheresis as part of a multimodality regimen: A single-centre experience.
Atzmony L; Amitay-Laish I; Gurion R; Shahal-Zimra Y; Hodak E
J Eur Acad Dermatol Venereol; 2015 Dec; 29(12):2382-9. PubMed ID: 26299651
[TBL] [Abstract][Full Text] [Related]
12. BCL2 and JUNB abnormalities in primary cutaneous lymphomas.
Mao X; Orchard G; Lillington DM; Child FJ; Vonderheid EC; Nowell PC; Bagot M; Bensussan A; Russell-Jones R; Young BD; Whittaker SJ
Br J Dermatol; 2004 Sep; 151(3):546-56. PubMed ID: 15377339
[TBL] [Abstract][Full Text] [Related]
13. Sézary syndrome without erythroderma: A review of 16 cases at Mayo Clinic.
Thompson AK; Killian JM; Weaver AL; Pittelkow MR; Davis MD
J Am Acad Dermatol; 2017 Apr; 76(4):683-688. PubMed ID: 28012574
[TBL] [Abstract][Full Text] [Related]
14. Sézary syndrome without erythroderma: A case report and review of published work.
Kamijo H; Miyagaki T; Norimatsu Y; Shishido-Takahashi N; Kuzumi A; Asano Y; Sato S
J Dermatol; 2019 Jan; 46(1):61-64. PubMed ID: 30379353
[TBL] [Abstract][Full Text] [Related]
15. p53 allele deletion and protein accumulation occurs in the absence of p53 gene mutation in T-prolymphocytic leukaemia and Sezary syndrome.
Brito-Babapulle V; Hamoudi R; Matutes E; Watson S; Kaczmarek P; Maljaie H; Catovsky D
Br J Haematol; 2000 Jul; 110(1):180-7. PubMed ID: 10930996
[TBL] [Abstract][Full Text] [Related]
16. Expression pattern of chemokine receptors and chemokine release in inflammatory erythroderma and Sézary syndrome.
Fierro MT; Comessatti A; Quaglino P; Ortoncelli M; Osella Abate S; Ponti R; Novelli M; Bernengo MG
Dermatology; 2006; 213(4):284-92. PubMed ID: 17135733
[TBL] [Abstract][Full Text] [Related]
17. Primary cutaneous T-cell lymphoma (mycosis fungoides and Sézary syndrome): part I. Diagnosis: clinical and histopathologic features and new molecular and biologic markers.
Jawed SI; Myskowski PL; Horwitz S; Moskowitz A; Querfeld C
J Am Acad Dermatol; 2014 Feb; 70(2):205.e1-16; quiz 221-2. PubMed ID: 24438969
[TBL] [Abstract][Full Text] [Related]
18. Diagnostic tools in Sezary syndrome.
Möbs M; Knott M; Fritzen B; Pullmann S; Sterry W; Assaf C
G Ital Dermatol Venereol; 2010 Jun; 145(3):385-91. PubMed ID: 20461046
[TBL] [Abstract][Full Text] [Related]
19. Utility of flow cytometry immunophenotyping and DNA ploidy studies for diagnosis and characterization of blood involvement in CD4+ Sézary's syndrome.
Lima M; Almeida J; dos Anjos Teixeira M; Queiros ML; Santos AH; Fonseca S; Balanzategui A; Justica B; Orfao A
Haematologica; 2003 Aug; 88(8):874-87. PubMed ID: 12935975
[TBL] [Abstract][Full Text] [Related]
20. [Analysis of cloning rearrangement of T-cell receptor gamma gene in primary cutaneous lymphoma].
Pawlaczyk M; Kistowska M; Poreba E; Filas V; Breborowicz J; Goździcka-Józefiak A
Pol Merkur Lekarski; 2003 Nov; 15(89):420-3. PubMed ID: 14969134
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]